| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1002: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over |
|
Medicine details |
|
| Medicine name | evinacumab (Evkeeza®) |
| Formulation | intravenous infusion |
| Reference number | 4042 |
| Indication | Adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH). |
| Company | Regeneron Pharmaceuticals Inc |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 31/01/2023 |
| NICE guidance | |